The U.S. Food and Drug Administration has given Roche approval to market its skin cancer drug Zelboraf and its lung cancer drug Alecensa.
Zelboraf is now approved for certain patients, those whose cancer cells have a genetic mutation known as BRAF V600, with rare blood cancer Erdheim-Chester Disease. It is the first FDA-approved treatment for the disease.
Alecensa has been approved as initial treatment for patients with a rare form of non-small cell lung cancer caused by a mutation to a gene known as ALK.
Read the Reuters report